Reapplix
  • About Reapplix
    • About Reapplix
    • About 3C Patch®
    • Executive Management
    • Board of Directors
    • Investors
  • News and press
  • Conferences
  • Contact
Select Page

Reapplix presents poster at Diabetic Foot Study Group meeting in Porto

Sep 1, 2017

The Reapplix team have the pleasure to participate at the 14TH ANNUAL MEETING OF THE DFSG, 8-10 September 2017.

A poster on the “Immunological perspectives of LeucoPatch treatment of Diabetic Foot Ulcer” will be presented.

← PRESS RELEASE: Reapplix announces new US FDA 510(k) clearance for expanded system, including automated centrifuge, a further advancement of its regenerative wound care technology Reapplix scientific team presented data at The Diabetic Lower Extremity Symposium →

RECENT POSTS

  • PRESS RELEASE: REAPPLIX ANNOUNCES APPOINTMENT OF RICHARD TWOMEY TO BOARD OF DIRECTORS 20/10/2020
  • PRESS RELEASE: REAPPLIX RECEIVES NEW REIMBURSEMENT CODING AND COMPLETES USD 22.6M EQUITY FINANCING TO DRIVE US COMMERCIALIZATION 14/07/2020
  • SmartTrak market analysis highlights Reapplix strong clinical data 13/11/2019
  • PRESS RELEASE: Reapplix 3C Patch® therapy recommended for enhancement of healing diabetic foot ulcers by international working group on the diabetic foot (IWGDF) 29/05/2019
  • Reapplix strengthens its Board of Directors and adds experienced profiles 06/03/2019

REAPPLIX INC / US

325 Miron Drive, Suite 140
Southlake, Texas 76092
USA

+1 877 629 3443
Mail to Reapplix US

VISIT OUR PRODUCT SITE 3CPATCH.COM

REAPPLIX A/S HQ / EUROPE

Blokken 45
3460 Birkerød
Denmark

+45 88 16 80 66
Mail to Reapplix Europe

© 2020 Reapplix A/S. All Rights Reserved. 3C Patch® and 3C Patch System® are registered trademarks of Reapplix A/S. For full safety information, please reference the 3C Patch® Instructions for Use. Privacy Policy.
X
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPrivacy policy